NEW YORK – Precision diagnostics company MDxHealth said on Wednesday that it has confidentially submitted a draft registration statement to the US Securities and Exchange Commission relating to a proposed initial public offering of American depositary shares in the US.
The company, which has headquarters in Herstal, Belgium, and Irvine, California, did not specify the number of ADSs it plans to offer, nor the timing or price for the proposed offering, but said it expects the public offering to take place after the SEC completes its review process.
In its recent earnings report for the first half of 2021, MDxHealth said its revenues increased 9 percent year over year, thanks largely to healthy increases in sales of its prostate cancer tests, SelectMDx and ConfirmMDx.